Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

被引：0
|
作者：
Maiolino, Angelo [1 ,2 ]
Da Costa, Elaine Sobral [1 ]
Orfao, Alberto [3 ,4 ]
机构：
[1] Univ Fed Rio de Janeiro, Dept Internal Med, Rio De Janeiro, Brazil
[2] Dept Hematol, Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil
[3] Univ Salamanca, NUCLEUS Inst Biomed Res Salamanca IBASAL, Canc Res Ctr IBMCC USAL CSIC, CIBERONC,Translat & Clin Res Program,Cytometry Ser, Salamanca, Spain
[4] Univ Salamanca, Dept Med, Salamanca, Spain
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
minimal residual disease; multiple myeloma; prognostic factor; disease monitoring; flow cytometry;
D O I：
10.3389/fonc.2023.1211935
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Insights into the Assessment of Measurable Residual Disease (MRD) in Patients With Multiple Myeloma
    Costa, Luciano J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 11 - 16
  • [2] The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
    Paiva, Bruno
    Cedena, Teresa
    Puig, Noemi
    Cordon, Lourdes
    Martinez-Lopez, Joaquin
    Ocio, Enrique M.
    Hernandez, Miguel T.
    Isabel Teruel, Ana
    Gironella, Mercedes
    Asuncion Echeveste, M.
    Rosinol, Laura
    Martinez, Rafael
    Oriol, Albert
    Martin, Jesus
    Gutierrez, Norma C.
    Belen Vidriales, Maria
    Blade, Joan
    Jose Lahuerta, Juan
    Mateos, Maria-Victoria
    San Miguel, Jesus
    BLOOD, 2015, 126 (23)
  • [3] Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
    Charalampous, Charalampos
    Kourelis, Taxiarchis
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [4] MINIMAL RESIDUAL DISEASE DETECTION BY NEXT GENERATION FLOW-MRD IN MULTIPLE MYELOMA PATIENTS
    Sirianni, S.
    Gozzetti, A.
    Candi, V.
    Bocchia, M.
    Raspadori, D.
    HAEMATOLOGICA, 2016, 101 : S87 - S87
  • [5] A sensitive technique for detection of minimal residual disease (MRD) in myeloma patients
    JeddiTehrani, M
    Gigliotti, D
    Osterborg, A
    Fagerberg, J
    Mellstedt, H
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 488 - 488
  • [6] Minimal residual disease (MRD) investigation in multiple myeloma - hype or real progress?
    Hose, D.
    Seckinger, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 244 - 245
  • [7] Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
    Samur, Mehmet K.
    Minvielle, Stephane
    Magrangeas, Florence
    Parmigiani, Giovanni
    Anderson, Kenneth C.
    Moreau, Philippe
    Attal, Michel
    Avet-Loiseau, Herve
    Munshi, Nikhil C.
    BLOOD, 2015, 126 (23)
  • [8] Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma: A Review of the Data
    Bal, Susan
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 3 - 10
  • [9] Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma: A Review of the Data
    Wolf, Jeffrey
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (03)
  • [10] Role of minimal residual disease assessment in multiple myeloma
    Szalat, Raphael E.
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    HAEMATOLOGICA, 2024, 109 (07) : 2049 - 2059
12345